Pasithea Therapeutics Corp. 8-K Summary
Business Context and Reporting Period
Pasithea Therapeutics Corp. (KTTA) filed this Current Report on Form 8-K on September 26, 2024, to disclose a material definitive agreement and unregistered sales of equity securities. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
The filing details a private placement that closed on September 30, 2024. Key financial terms include:
- Net Proceeds: Approximately $4.5 million after deducting placement agent fees and estimated offering expenses.
- Securities Issued:
- 1,219,513 Pre-Funded Warrants (exercise price $0.001).
- 1,219,513 Series A Warrants (exercise price $3.85, 5-year term).
- 1,219,513 Series B Warrants (exercise price $3.85, 18-month term).
- Combined Purchase Price: $4.099 per Pre-Funded Warrant and accompanying Warrants.
- Placement Agent Fees: H.C. Wainwright & Co., LLC received a 7.0% cash fee, a 1.0% management fee, $50,000 for expenses, and warrants to purchase 85,366 shares at $5.125 per share.
Material Changes and Agreements
The company entered into a Securities Purchase Agreement and a Registration Rights Agreement. The company agreed to file a registration statement for the resale of underlying shares within 15 days of the agreement and use best efforts to have it declared effective within 45 days (or 90 days in the event of a full SEC review). The filing does not provide comparative financial data (revenue, profit, cash flow) as this is a transactional report rather than a periodic financial statement.
Outlook, Risks, and Use of Proceeds
The company intends to use the net proceeds for working capital and general corporate purposes. The transaction includes a 90-day lock-up period on issuing new common stock or equivalents and a 6-month restriction on Variable Rate Transactions following the effective date of the registration statement. Beneficial ownership limitations restrict exercise if the holder would own more than 4.99% (or 9.99% with notice) of outstanding shares.
Investor Verification Checklist
- Verify the effective date of the registration statement filed to register the resale of shares underlying the warrants.
- Confirm the total number of shares outstanding post-closing to assess dilution from the 1,219,513 Pre-Funded Warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Monitor the company's cash burn rate to determine if the $4.5 million in proceeds extends the runway as intended.